BridgeBio Pharma, Inc. expected to post a loss of 59 cents a share - Earnings Preview

What happened

BridgeBio Pharma is expected to report results on October 29 for the quarter ended September 30, 2026. Analysts expect revenue to rise 136.5% to $285.497 million from $120.7 million a year ago, and a loss of 59 cents per share.

Confirmed

Global impact / market context

The projected revenue jump suggests BridgeBio is selling far more than a year earlier, while the expected 59-cent loss shows costs still exceed revenue. If the actual loss is larger than expected, as in recent quarters, the stock could face pressure.

Analyst inference

Analysts rate the shares "buy" on average: 21 buy or strong buy, 2 hold, and no sell. The median 12-month price target is $108.50, about 59.2% above the last close of $68.15, signaling analyst optimism.

Analyst inference

What to watch

1. Watch whether reported revenue reaches the $285.497 million mean estimate from 18 analysts, and whether the loss per share is 59 cents or worse than expected. Confirmed
2. Watch whether management's guidance on future sales and spending points to narrowing losses, which would show progress toward profitability. Proposed
3. Watch cash needs: repeated losses could force BridgeBio to raise money by selling shares or borrowing, which may dilute existing shareholders or add interest costs. Analyst inference

Evidence

• Original source link unavailable